Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies

Large B cell lymphoma (LBCL) is curable with standard chemo-immunotherapy in the majority of cases. However, patients with primary refractory or relapsed disease have historically had limited treatment options. Two gene-modified chimeric antigen receptor (CAR)-T cell therapies have now been approved...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mol Ther
Main Authors: Leick, Mark B., Maus, Marcela V., Frigault, Matthew J.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Gene & Cell Therapy 2021
Teme:
Clinical Perspective
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7854294/
https://ncbi.nlm.nih.gov/pubmed/33130313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.10.022
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki